Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 9/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.69 |
| ▸ | KIT | P10721 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 8/20 | 0.65 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.63 |
| ▸ | MET | P08581 | 2/20 | 0.62 |
| ▸ | AURKA | O14965 | 1/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.62 |
| ▸ | LCK | P06239 | 1/20 | 0.62 |
| ▸ | LYN | P07948 | 1/20 | 0.62 |
| ▸ | TEK | Q02763 | 1/20 | 0.62 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.62 |
| ▸ | AXL | P30530 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3794599 | 0.87 | FGFR2 (0.69) | PDGFRAPDGFRBKITKDRFGFR2 | |
| SCHEMBL21358445 | 0.86 | PDGFRA (0.58) | PDGFRAPDGFRBKITKDRFGFR2 | |
| SCHEMBL6228087 | 0.84 | PDGFRA (0.79) | PDGFRAKITKDRFGFR2MET | |
| SCHEMBL28428914 | 0.83 | PDGFRA (0.49) | PDGFRAPDGFRBKITKDRFGFR2 | |
| SCHEMBL7486400 | 0.83 | FGFR2 (0.84) | PDGFRAPDGFRBKDRFGFR2 | |
| SCHEMBL7485158 | 0.83 | FGFR2 (0.71) | PDGFRAPDGFRBKITKDRFGFR2 | |
| SCHEMBL14808762 | 0.83 | AURKB (0.67) | PDGFRAPDGFRBKITKDRFGFR2 | |
| SCHEMBL14967325 | 0.82 | PDGFRA (0.74) | PDGFRAPDGFRBKDRFGFR2MET | |
| SCHEMBL4470477 | 0.82 | PDGFRA (0.74) | PDGFRAPDGFRBKDRFGFR2 | |
| SCHEMBL167396 | 0.82 | PDGFRA (0.74) | PDGFRAPDGFRBKDRFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116763787-A | New application of quinoline compound | 安徽中科拓苒药物科学研究有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-111303024-B | Quinoline-structured pan-KIT kinase inhibitor and application thereof | 安徽中科拓苒药物科学研究有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20220064117-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | Tarapeutics Science Inc. (CN) | 2022-03-03 | — | — | US | disclosed |
| EP-3896059-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | Tarapeutics Science Inc. (CN) | 2021-10-20 | — | — | EP | disclosed |
| CN-111303024-A | Quinoline-structured pan-KIT kinase inhibitor and application thereof | 安徽中科拓苒药物科学研究有限公司 | 2020-06-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064117-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | KIT, MAP3K7, ABL1 | PDGFRA 747/4885PDGFRB 943/4885KIT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.